Voltron Therapeutics, Inc. Announces COVID-19 and Pandemic Preparedness Presentation

Voltron Therapeutics, Inc announces COVID-19 and pandemic preparedness presentation to congressional offices and agencies, including HHS, NIH, FDA, and DoD.

Presenters included VIC’s Mark C. Poznansky, MD, PhD, FRCP, FIDSA, Michael V. Callahan, MD, MSPH, DTM&H and Patrick M Reeves, PhD discussing state of the art vaccines for COVID-19 and variants.

“NEW YORK, April 13, 2021 (GLOBE NEWSWIRE) — Voltron Therapeutics, Inc. today announced that the Company presented to Congressional Offices and Agencies, including HHS, NIH, FDA and the DoD on Thursday April 8th. This follows dozens of recent one-on-one briefings with Congressional staffers.

Presentations focused on current challenges being faced by governments due to COVID-19 mutations and why further vaccine development and innovation, especially in vaccine platforms, is vital. This is not just true for COVID-19, but for emerging variants and future pandemic pathogens. Panelists also discussed a potential solution under development that is based on Self-Assembling Vaccine technology developed at Harvard and Massachusetts General Hospital’s Vaccine and Immunotherapy Center and licensed by Voltron. This technology is designed to ensure that the US is ready to protect both citizens and warfighters from existing, emerging and mutating pathogens.”

J&J vaccine: Convenience at a price?

Mark Poznansky interviewed by Jim Morelli for the Boston 25 News: J&J vaccine: Convenience at a price? Regulators look into reports of serious clots.

“BOSTON — It promised convenience, ease of storage and protection against serious COVID-19 illness. And by all accounts, Johnson & Johnson/Janssen’s single-dose vaccine is living up to those claims. But is all that coming with a price?

U.S. regulators now have the difficult task of figuring out whether six cases of cerebral blood clots that developed just weeks after immunization are an actual side effect of the vaccine.

“In the general population this condition exists in the absence of vaccination and is a very rare condition,” said Dr. Mark Poznansky, director of Mass General’s Vaccine and Immunotherapy Center. “When you start vaccinating lots of people, you can get these sort of findings. And it’s really incumbent upon the FDA to work out is it cause or is it just a random association?””